Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors

Pharmacogenomics

Volumn 13, Issue 9, 2012, Pages 1009-1021

  Mitra, Amit K ^a   Kirstein, Mark N ^a,b   Khatri, Amit ^a   Skubitz, Keith M ^b,c   Dudek, Arkadiusz Z ^b,c   Greeno, Edward W ^b,c   Kratzke, Robert A ^b,c   Lamba, Jatinder K ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

cytidine deaminase; deoxycytidine kinase; gemcitabine; pharmacogenomics; pharmacokinetics

Indexed keywords

2',2' DIFLUORO 2' DEOXYCYTIDINE TRIPHOSPHATE; 2',2' DIFLUORODEOXYURIDINE; BORTEZOMIB; CARBOPLATIN; DNA; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CDA GENE; CLINICAL ARTICLE; CMPK GENE; DCK GENE; DCTD GENE; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; NT5C2 GENE; NT5C3 GENE; OVARY CANCER; PANCREAS CANCER; PHARMACOGENOMICS; SARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SLC28A1 GENE; SLC28A3 GENE; SLC29A1 GENE; SOLID TUMOR;

5'-NUCLEOTIDASE; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; FLOXURIDINE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84864411377     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.81     Document Type: Article

References (20)

1. Dumontet C, Morschhauser F, Solal-Celigny P et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br. J. Haematol. 113(3), 772-778 (2001).
2. Metro G, Cappuzzo F, Finocchiaro G, Toschi L, Crino L. Development of gemcitabine in non-small cell lung cancer: the Italian contribution. Ann. Oncol. 17(Suppl. 5), V37-V46 (2006).
3. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark. Med. 5(6), 795-806 (2011).
4. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann. Oncol. 17(Suppl. 5), V7-V12 (2006).
5. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 22(4 Suppl. 11), 3-10 (1995).
6. Rosell R, Cobo M, Isla D, Camps C, Massuti B. Pharmacogenomics and gemcitabine. Ann. Oncol. 17(Suppl. 5), V13-V16 (2006).
7. Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, Dolzan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.Pharmacogenet. Genomics 22(1), 58-68 (2012).
8. Wong AL, Yap HL, Yeo WL et al. Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. Cancer Genomics Proteomics 8(5), 255-259 (2011).
9. Kirstein MN, Hassan I, Guire DE et al. High-performance liquid chromatographic method for the determination of gemcitabine and 2́,2́-difluorodeoxyuridine in plasma and tissue culture media. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 835(1-2), 136-142 (2006).
10. Veltkamp SA, Hillebrand MJ, Rosing H et al. Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J. Mass Spectrom. 41(12), 1633-1642 (2006).
11. Cheung RK, Grinstein S, Gelfand EW. Volume regulation by human lymphocytes. Identification of differences between the two major lymphocyte subpopulations. J. Clin. Invest. 70(3), 632-638 (1982).
12. Tham LS, Wang L, Soo RA et al. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin. Cancer Res. 14(13), 4213-4218 (2008).
13. Mitra AK, Crews KR, Pounds S et al. Genetic variants in cytosolic 5́-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J. Pharmacol. Exp. Ther. 339(1), 9-23 (2011).
14. Li L, Schaid DJ, Fridley BL et al. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet. Genomics 22(2), 105-116 (2012).
15. Ludovini V, Floriani I, Pistola L et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J. Thorac. Oncol. 6(12), 2018-2026 (2011).
16. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin. Cancer Res. 16(1), 320-329 (2010).
17. Soo RA, Wang LZ, Ng SS et al. Distribution of gemcitabine pathway genotypes in ethnic asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 63(1), 121-127 (2009).
18. Tibaldi C, Giovannetti E, Tiseo M et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann. Oncol. 23(3), 670-677 (2012).
19. Ryu JS, Shin ES, Nam HS et al. Differential effect of polymorphisms of cmpk1 and rrm1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. J. Thorac. Oncol. 6(8), 1320-1329 (2011).
20. Gusella M, Pasini F, Bolzonella C et al. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br. J. Clin. Pharmacol. 71(3), 437-444 (2011).